WASHINGTON, DC— 1792 Exchange – alongside organizations including Alliance Defending Freedom (ADF) and the Heritage Foundation – is facilitating the participation of detransitioners at major corporate annual meetings to provide critical testimony on shareholder proposals concerning gender medical interventions.
On Tuesday, April 28, 2026, detransitioner Camille Kiefel spoke at IBM’s annual shareholder meeting in support of the Heritage Foundation’s Proposal 8. The proposal requests that IBM issue a comprehensive report analyzing the benefits, costs, and risks, including legal, reputational, and discriminatory impacts, associated with the company’s charitable contributions and corporate policies supporting gender medical interventions.
Kiefel, who underwent a double mastectomy after identifying as non-binary and is now a prominent advocate for caution against sex-denying procedures shared her personal experience. Her testimony underscores the growing medical, legal, and cultural concerns surrounding these interventions, particularly for minors.
“Policies that enable these interventions for minors carry legal, ethical, and human consequences,” Kiefel stated. “When I turned to medical providers and asked about transitioning, the focus was not on understanding me but affirming me to surgery. How can someone make an informed decision if they are not given all the information? They can’t. Yet this is the standard way in which providers under IBM’s current healthcare plans appear to treat their young patients.”
Kiefel referenced the increasing number of detransitioner lawsuits, at least 25 filed since 2022, and noted action by Walmart, which has updated its healthcare plans to exclude coverage of these interventions for minors. Kiefel questioned whether IBM has adequately assessed the associated risks, especially given its perfect 100/100 score on the Human Rights Campaign’s 2026 Corporate Equality Index (CEI), which the proposal critiques for promoting coverage of puberty blockers, cross-sex hormones, and surgeries.
This engagement is part of 1792 Exchange’s broader initiative to encourage corporations to return to ideological neutrality on divisive social issues, thereby better protecting shareholders, employees, customers, and families from policies that support experimental medical interventions on minors.
Douglas Napier, CEO of 1792 Exchange, added: “1792 Exchange is committed to equipping shareholders and corporations with the information needed to prioritize business neutrality, risk management, and long-term value creation over ideological activism. Camille Kiefel’s courageous testimony highlights the real human costs of unchecked corporate alignment with activist-driven policies. We urge IBM and other companies to thoroughly evaluate these risks, learn from emerging legal precedents and corporate course corrections like Walmart’s, and adopt policies grounded in evidence, caution, and respect for all stakeholders.”
###
1792 Exchange – America’s leading provider of actionable data on corporate bias – is a 501(c)(3) nonprofit that advances free speech, free exercise, and free enterprise by steering companies back to neutral on ideological issues.